UNSPSC 51334402: Biriperone

This classification denotes an anxiolytic with the molecular formula C24H26FN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5776HBV7UD, chemically known as pyrazino(1,2:1,6)pyrido(3,4-b)indole, 1,2,3,4,6,7,12,12a-octahydro-2-(3-(p-fluorobenzoyl)propyl)-, dl- but generally known as biriperone, which bears US NIH Compound Identifier 68663. European Medicines Agency schedules Biriperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05845MIG.

UNSPSC 51334402 Biriperone is a Commodity code that in recent state and local procurement activity covers pharmaceutical products and related health-system supplies, though the code's nominal scope and the actual solicitations show significant divergence. State and local governments purchasing under this code are acquiring naloxone and drug deactivation systems for community health programs, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and exploring direct-to-manufacturer prescription fulfillment models. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities including Oregon). The code shows activity across health and human services procurement, with county health initiatives and state-level pharmaceutical supply chain modernization as the primary drivers.

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent solicitations. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with awarded vendors effective July 1, 2026. The MMCAP solicitation emphasizes price competitiveness (75 percent weight), cGMP and DSCSA compliance, and maintenance of relationships with specified wholesalers, while the Seminole County IFB requires E-Verify compliance, drug-free workplace certification, and specific insurance coverages.